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Introduction
Breast density, assessed by mammography and expressed 
as a percentage of the mammogram occupied by radio-
logically dense tissue (percent mammographic density, or 
PMD), reﬂ   ects variations in breast tissue composition 
and is strongly associated with breast cancer risk [1]. 
Here, we review the evidence that PMD is a risk factor 
for breast cancer, histological and other factors associated 
with variations in PMD, and the biological plausibility of 
the associations with risk of breast cancer. We discuss the 
potential clinical applications of this risk factor in 
screening, in research on breast cancer prevention, and 
in risk prediction in individuals. Mammographic density 
has been the subject of a meta-analysis (see next section) 
[1] and a recent review [2] and readers are referred to 
these sources for additional information.
Mammographic density and risk of breast cancer
Th  e radiographic appearance of the breast on mammo-
graphy varies among women, as illustrated in Figure 1, 
and reﬂ  ects variations in breast tissue composition and 
the diﬀ   erent x-ray attenuation characteristics of these 
tissues [3]. Fat is radiologically lucent and appears dark 
on a mammogram. Connective and epithelial tissues are 
radiologically dense and appear light. Th   is appearance is 
usually expressed as a percentage of the breast area, or 
(as referred to here) as percent mammographic density 
(PMD).
In a systematic meta-analysis of data for more than 
14,000 cases and 226,000 non-cases from 42 studies, 
McCormack and dos Santos Silva [1] reviewed the data 
on the association of PMD with risk of breast cancer. Th  e 
authors found that PMD was consistently associated with 
risk of breast cancer. Associations were stronger in 
studies in the general population rather than sympto-
matic women, in studies of incident rather than prevalent 
cancer, and for percent density rather than Wolfe’s 
classiﬁ  cation. Wolfe was the ﬁ  rst to describe diﬀ  erences 
in breast cancer risk associated with variations in the 
mammographic appearance of the breast [4,5]; he used 
four categories: N1 (predominately fat), P1 and P2 (ductal 
prominence in less than 25% or more than 25% of the 
breast, respectively), and DY (extensive ‘dysplasia’). A 
quantitative method of measur  ing breast density, 
Cumulus, is illustrated in Figure 1. Th   resholds placed at 
the edge of the breast (red line) and the edge of density 
(green line) are used to calculate PMD [6].
Table  1 summarizes selected features of the cohort 
studies, or studies nested within cohorts, that used 
quanti  tative methods to classify PMD [7-15]. Th  e 10 
studies shown were carried out in the US, Europe, or 
Canada and all found a statistically signiﬁ  cant increase in 
risk associated with more extensive PMD after 
adjustment for other risk factors, and the increase in risk 
persisted for at least 8 to 10 years from the date of the 
mammogram used to classify PMD [9,15]. Th   ere is also 
evidence of a dose-response relationship (that is, of risk 
increasing with increasing PMD).
Other qualitative classiﬁ   cations, such as the four-
category system developed by the American College of 
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or BI-RADS), also create groups with diﬀ  erent risks of 
breast cancer [16,17]. Th  e BI-RADS classiﬁ  cation  of 
mammographic density has four categories: (1) almost 
entirely fatty, (2) scattered ﬁ  broglandular densities, (3) 
heterogeneously dense, and (4) extremely dense. BI-
RADS is the only classiﬁ  cation of mammographic density 
currently in clinical use in the US but, of the available 
methods, appears to be the least reliable. Reliability 
between readers is modest (kappa statistic = 0.56) [18], 
whereas the interclass correlation coeﬃ   cient for trained 
readers using Cumulus is more than 0.9 [15]. None  the-
less, the BI-RADS classiﬁ  cation does distinguish women 
at diﬀ  erent risks for the development of breast cancer, 
and a summary by Cummings and colleagues [17] esti-
mated a fourfold gradient in risk between BI-RADS 
categories 1 and 4.
As shown in Table 2, PMD is associated with risk of 
breast cancer both at screening and between screening 
examinations. In the three Canadian studies shown in 
Table 1 [15], the method of breast cancer detection was 
recorded by each of the programs. We used those 
classiﬁ  cations to subdivide the breast cancers into those 
detected at screening, those detected within 12 months 
of a negative screen, and those detected more than 
12 months after a negative screening examination. In a 
compari  son of those with less than 10% density and those 
with more than 75% density, the odds ratio was 4.74 (95% 
conﬁ  dence interval (CI) 3.0, 7.4) for all cancers. In the 
717 cases of breast cancer detected at screening, the odds 
ratio was 3.52 (95% CI 2.0, 6.2). In the 124 cases of breast 
cancer detected within 12 months of the last screening 
examination, the odds ratio for risk of breast cancer in 
those with more than 75% density was 17.81 (95% CI 4.8, 
65.9). For cancers detected more than 12 months after 
the last screen, the odds ratio for those with more than 
75% density was 5.68 (95% CI 2.1, 15.5). Within each 
category of detection, there was a monotonic increase in 
risk with each category of density, and the trend tests 
were all highly signiﬁ  cant. Similar results were seen in 
each of the three screening programs.
More extensive PMD was thus associated with an 
increased risk of breast cancer at screening, in the 
presence of potential masking by density. Th  e marked 
elevation in risk associated with PMD in the 12 months 
after a negative screening examination does, however, 
probably reﬂ  ect the masking of tumors by density. Th  e 
annual incidence of breast cancer associated with 
diﬀ  erent degrees of density may be best estimated by 
combining the incident cancers detected at screening 
with those found by other methods in the 12 months 
following screening [15].
Comparison with other risk factors
Relative risk
Among other menstrual, reproductive, and familial risks 
of breast cancer, only age and BRCA carrier status are 
associated with larger relative risks of breast cancer than 
PMD (for example, [19]). Th   e relative risk associated with 
density is substantially larger than the relative risk of 
Figure 1. Examples of mammographic density. (a) 0% mammographic density, (b) less than 10%, (c) less than 25%, (d) less than 50%, (e) less 
than 75%, and (f) greater than 75%. On the right is an illustration of Cumulus in the measurement of mammographic density. The red line outlines 
the breast, and the green line outlines the area of density. Republished with permission from [2].
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disease or any of the menstrual and reproductive risk 
factors.
Attributable risk
Because extensive PMD is common in the population 
and associated with a large relative risk, if the association 
with breast cancer risk is causal, the proportion of the 
disease attributable to this risk factor is expected to be 
substantial. According to data from three Canadian 
screen  ing programs [15], the risks of breast cancer 
attributable to density of 50% or more were 16% for all 
cancers, 12% for screen-detected cancers, 40% for 
cancers detected within 12 months of a negative screen, 
and 16% for cancers detected more than 12 months after 
a screening examination.
For women below the median age of 56 years, the 
prevalence of density of 50% or more was about three 
times greater than in older women, in each category of 
detection, and the attributable risks of breast cancer were 
26% for all cancers, 21% for screen-detected cancers, 50% 
for cancers detected within 12 months of a negative 
screen, and 28% for cancers detected more than 12 
months after a screening examination. Similar estimates 
Table 1. Selected characteristics of cohort studies with quantitative classifi  cation of percent mammographic density 
Authors/study,   Subject age,   Sample      OR  Follow-up,  
region years  sizea Measurementb Partitionc (95%  CI)  years  Adjustmentsd
Kato et al. [7], USA 35-65 197/521 Planimetry Upper versus 
lower tertile
3.6 (1.4 to 9.1) 5.5 BMI, parity, and 
menopause
Saftlas et al. [8], 
USA
35-74 266/301 Planimetry <5% versus 
≥65%
4.3 (2.1 to 8.8) 5 Age, weight, and parity
Byrne et al. [9], 
USA
35-74 1,880/2,152 Planimetry 0% versus 
≥75%
4.3 (3.1 to 6.1) 10 Weight, age at fi  rst birth, 
family history, years of 
education, alcohol use, 
previous benign biopsies, 
and reproductive years
Torres-Mejia et al. 
[10], Europe
40-80 111/3,100 Computer-assisted 0.5% versus 
>46%
3.5 (1.4 to 5.2) 14 Age, education, parity, 
height, and BMI
van Gils et al. [11], 
Europe
>45 129/517 Automated <5% versus 
>25%
2.9 (1.6 to 5.6) 10 Age and parity
Thomas et al. [12], 
USA 
<50 547/472 Estimation Upper versus 
lower quartiles
4.4 (3.0 to 6.7) >6 Age and study
Maskarinec et al. 
[13], USA 
60e 607/667 Computer-assisted <10% versus 
>50%
3.6 (2.3 to 5.6) 7 Ethnicity, age, BMI, age 
at fi  rst birth, number of 
births, age at menarche, 
age at menopause, HRT, 
and family history of 
breast cancer 
Boyd et al./NBSS 
[14], Canada
40-59 330 a. Estimation
b. Computer-assisted
0% versus 
≥75%
a. 6.0 (2.8 to 13.0)
b. 4.0 (2.1 to 7.7)
7 Age, parity, age at fi  rst 
birth, weight, height, 
number of births, age 
at menarche, and family 
history
Boyd et al./SMPBC 
[15], Canada
40-70 398 a. Estimation
b. Computer-assisted
<10% versus 
≥75%
a. 4.5 (1.9 to 11.0)   
b. 4.4 (2.1 to 5.0)
6 Age, parity, age at fi  rst 
birth, weight, height, 
number of births, age 
at menarche, and family 
history
Boyd et al./OBSP 
[15], Canada
50-69 386 a. Estimation
b. Computer-assisted
<10% versus 
≥75%
a. 3.4 (1.1 to 10.3)
b. 4.1 (2.0 to 8.6)
8 Age, parity, age at fi  rst 
birth, weight, height, 
number of births, age 
at menarche, and family 
history
Boyd et al./
Combined [15], 
Canada
40-70 1,114 a. Estimation
b. Computer-assisted
<10% versus 
≥75%
a. 4.7 (3.0 to 7.4)
b. 4.4 (2.9 to 6.7)
6-8 Age, parity, age at fi  rst 
birth, weight, height, 
number of births, age 
at menarche, and family 
history
aReported as the number of case subjects/number of control subjects or as the number of pairs of case and control subjects. bEstimation means visual estimation 
by an observer (radiologist). cThe most and least extensive categories of density from which odds ratios (ORs) were calculated. dFactors included in the analysis of 
risk associated with mammographic density. Factors controlled for by matching are also included. eAverage age. Table reproduced from [2]. BMI, body mass index; 
CI, confi  dence interval; HRT, hormone replacement therapy; NBSS, National Breast Screening Study; OBSP, Ontario Breast Screening Program; SMPBC, Screening 
Mammography Program of British Columbia. Republished with permission from [2].
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Breast Cancer Detection and Demonstration project [9]. 
Th   ese estimates of attributable risk are larger than for any 
other risk factor for breast cancer, including BRCA 
carrier status, which is estimated to be responsible for 5% 
or less of all breast cancer [20,21].
Biological plausibility of the association of 
mammographic density and breast cancer risk
Hypotheses concerned with the biological basis of the 
association of PMD with risk of breast cancer have been 
reviewed elsewhere [22] and will be discussed only brieﬂ  y 
here. Th   e change in PMD with age reﬂ  ects the reduction 
in glandular tissue and accompanying increase in fat 
which occur with increasing age. Th   is decline in the risk 
factor of density with age may seem paradoxical, as breast 
cancer incidence increases with age. However, cumulative 
exposure to PMD reﬂ  ects cumulative exposure of breast 
stroma and epithelium to hormonal and growth factor 
stimuli to cell division. Cumulative exposure to PMD 
increases with age and may be related to the age-speciﬁ  c 
incidence of breast cancer [23].
As reviewed in [22], PMD is also less extensive in 
women who are parous and in those with a larger number 
of live births and is reduced by menopause. After 
adjustment for age and other potential inﬂ  uences,  a 
family history of breast cancer is associated with a more 
extensive PMD [24]. PMD has consistently been found to 
be inversely asso  ciated with body weight. Greater birth 
weight and adult height have been shown to be positively 
associated with PMD [25,26] and with an increased risk 
of breast cancer [27]. With the exception of weight, PMD 
may be on the causal pathway for breast cancer for some 
or all of these other risk factors.
Many of the factors that are associated with PMD are 
also associated with alterations in exposure to hormones 
that may inﬂ  uence the number and proliferative state of 
epithelial and stromal cells in the breast. To date, most 
studies of blood levels of ovarian hormones have found 
either no association or an inverse association with PMD 
in premenopausal or postmenopausal women (reviewed 
in [22]). Positive associations with PMD have been found 
between serum levels of growth hormone and breast 
water (a surrogate for PMD) in young women from 15 to 
30 years old [28], and serum insulin-like growth factor I 
(IGF-I) levels in premenopausal women and postmeno-
pausal women, and with serum levels of prolactin in 
postmenopausal women (reviewed in detail in [22]).
Radiologically dense breast tissue – in addition to 
greater amounts of collagen and cells and greater stained 
Table 2. Mammographic density and risk of breast cancer according to method of detection: unmatched analysis and 
radiologists’ classifi  cation of density
          Categories of percent
         density,  percentage
   Number  of
   pairsa  <10  10 to <25  25 to <50  50 to <75  >75  P valueb 
All Case  1,112  230  272  336  178  96 
 Control  1,112  362  270  290  144  46 
 ORc    1  1.75 2.06  2.43 4.74 <0.0001
  (95% CI)      (1.4, 2.2)  (1.6, 2.6)  (1.8, 3.3)  (3.0, 7.4)
Screen-detected Case  717  173  171  219  102  52 
 Control  717  242  162  196  88  29 
 ORc    1  1.65 1.77  1.98 3.52 <0.0001
  (95% CI)      (1.2, 2.2)  (1.3, 2.4)  (1.3, 2.9)  (2.0, 6.2)
Non-screen-detected <12 monthsd  Case  124  12 22 33  32 25 
 Control  124  35  29  29  23  8 
 ORc   1  2.11  3.61  5.65  17.81  <0.0001
  (95% CI)      (0.9, 5.2)  (1.5, 8.7)  (2.1, 15.3)  (4.8, 65.9)
Non-screen-detected >12 monthse  Case  262  43 79 80  42 18 
 Control  262  82  79  62  30  9 
 ORc    1  2.00 2.64  3.13 5.68 <0.0001
  (95% CI)      (1.2, 3.4)  (1.5, 4.6)  (1.6, 6.2)  (2.1, 15.5)
aNine pairs were excluded from the screen or non-screen group analysis because of missing information on detection (n = 1) or the last mammogram date (n = 8). bP 
value for the Cochran-Armitage trend test. cAdjusted for age, body mass index, age at menarche, parity, number of live births, age at fi  rst birth, menopausal status, 
age at menopause, hormone replacement therapy (ever/never), breast cancer in fi  rst-degree relatives (0, 1, and 2+), study (National Breast Screening Study, Ontario 
Breast Screening Program, and Screening Mammography Program of British Columbia), and observation time (2 years, 2 to 4 years, and greater than 4 years). dCancers 
detected within 12 months of the last screening date. eCancers detected 12 months or more after the last screening date. Table reproduced from [15]. CI, confi  dence 
interval; OR, odds ratio. Republished with permission from [15].
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greater amounts of the tissue inhibitor metalloprotease 3 
(TIMP-3) [29]. Aromatase immunoreactivity is also 
associated with dense breast tissue [30]. Th  e 
proteoglycans lumican and decorin have been associated 
with breast cancer and have also been found to be present 
in greater amounts in women with extensive PMD [31].
Mammographic density and risk of histological 
precursors to breast cancer
Mammographic density reﬂ  ects the proportions of fat, 
stromal, and epithelial tissue in the breast and does not 
denote any histological abnormality [32,33]. Extensive 
mammographic density is, however, associated with 
increased risks for the development of most of the 
histological abnormalities that are non-obligate precur-
sors of breast cancer. Th   e breast lesions of ductal carci-
noma  in situ (DCIS), atypical hyperplasia, hyperplasia 
without atypia, and columnar cell lesions (CLLs) are, to 
diﬀ  erent degrees, associated with an increased risk of 
breast cancer, and, as discussed below, risk of each type 
of lesion is also increased by extensive PMD.
In the Multiethnic cohort, women with more than 50% 
PMD had, compared with those with less than 10% PMD, 
an increased risk of both invasive breast cancer (OR = 
3.58; 95% CI 2.3, 5.7) and DCIS (OR = 2.9; 95% CI 1.4, 
5.9) [26]. A case control study in the Canadian National 
Breast Screening Study showed that, in women with 
more than 75% density, compared with those with no 
density, risk of in situ breast cancer and atypical 
hyperplasia combined was greater (OR = 9.7; 95% CI 1.7, 
53.9), as was risk of hyperplasia without atypia (OR = 
12.2; 95% CI 2.9, 50.1) [34]. Additional studies have also 
shown PMD to be associated with risk of DCIS [35,36].
CLL, thought to be the earliest recognizable histolo-
gical feature that is a non-obligate precursor to breast 
cancer, has been found to be more frequent (OR = 2.2; 
95% CI 1.03, 4.8) in biopsies from breasts with more than 
the median density of 30%. CLLs were also strongly 
positively associated with the percentage of the biopsy 
occupied by collagen (P = 9.2 × 10−5) and glandular area 
(P = 2 × 10−5) [37]. Age-related atrophy of breast lobules 
(lobular involution) has been found to be inversely 
associated with risk of breast cancer [38], and it appears 
that PMD and lobular involution are independently 
associated with risk of breast cancer [39].
Future prospects
Potential improvements in measuring breast tissue 
composition
All of the methods currently used to assess breast density 
by mammography have limitations. None takes into 
account the thickness of the breast, and all are based on 
the projected area, rather than the volume, of breast 
tissue. All current methods depend upon a trained 
observer and thus are subjective. Th  ese  potential  sources 
of error in measurement are likely to attenuate the 
observed associations between percent PMD and other 
risk factors for breast cancer and risk of the disease itself.
To date, three published case control studies have 
examined the association between percent PMD and risk 
of breast cancer by measuring breast tissue volumes. One 
used standard mammography form (SMF) software that 
uses information about the non-fat tissue in the breast, in 
conjunction with the thickness of the compressed breast 
and the breast imaging variables of tube voltage and 
exposure time, to generate estimates of breast tissue 
volumes [40]. In an alternative approach to the measure-
ment of tissue volumes, we acquired images prospectively 
from mammography machines cali  brated to allow 
examination of the relationship between the image signal 
in each pixel (that is, optical density or blackness of the 
processed ﬁ   lm value), the exposure factors (that is, 
kilovoltage, milliampere-seconds, tube target, and beam 
ﬁ  lter), and the amount of radiation transmitted by the 
breast. Corrected breast tissue thickness and breast 
tissue volumes were calculated [41].
In two of these studies, the volume-based measures of 
percent density were associated with breast cancer risk, 
though less strongly than the area-based measures of 
percent density. It is not yet clear whether these results 
reﬂ  ect as-yet-uncorrected errors in the measurement of 
breast tissue volumes or the failure to capture additional 
breast risk information that is present in the area-based 
measures. An alternative method of measuring percent 
ﬁ   broglandular tissue volumes by using single x-ray 
absorptiometry has been shown to more accurately 
predict breast cancer risk than percent dense area [42] 
but has not yet been replicated or applied to digital 
mammograms. Other methods of measuring tissue 
volumes are under development [43,44].
Potential alternatives to the assessment of breast tissue 
composition by mammography include measurement of 
the breast water (reﬂ   ecting the stromal and epithelial 
tissue) and fat content by magnetic resonance (MR) and 
ultrasound tomography (UST). Both have been discussed 
elsewhere as alternatives to mammography in measuring 
density [2]. Percent PMD in the mammogram is strongly 
correlated both with percent water by MR (Spearman r = 
0.85;  P <0.001) [45] and average sound speed by UST 
(Spearman r = 0.77; P <0.001) [46].
Etiology of mammographic density
Because PMD is strongly associated with risk of breast 
cancer, factors that inﬂ  uence PMD may also contribute to 
the causes of breast cancer, and the identiﬁ  cation  of 
factors that change PMD may lead to the identiﬁ  cation of 
factors that can reduce the incidence of breast cancer. 
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bility of the association of mammographic density and 
breast cancer risk’ section above) account for only 20% to 
30% of the PMD variation observed in the population 
[47], and genetic factors might explain a proportion of 
variation (that is, the heritability) of PMD. Two large, 
twin studies have added to the evidence that PMD is a 
heritable quantitative trait. In one, 951 twin pairs (age 
range of 40 to 70 years) in Australia and North America 
were recruited, and mammograms and information on 
the factors associated with variations in PMD were 
collected. After adjustment for age and other covariates, 
the proportion of the residual variation in PMD 
accounted for by additive genetic factors (heritability) 
was estimated to be 63% (95% CI 59% to 67%) in the 
combined studies [48]. In a second study, with 553 twin 
pairs, the propor  tion of the residual variation in PMD 
heritability was estimated to be 53% [49]. Research now 
in progress seeks to identify genetic variants associated 
with PMD, and, of the 12 single-nucleotide polymor-
phisms reproducibly asso  ciated with risk of breast cancer, 
at least 3 have been found to be also associated with 
PMD [50,51].
Understanding of biological mechanisms
Epithelial and stromal cells, collagen, and fat are the 
tissue components that contribute to variations in PMD. 
Th   e twin studies described in the previous section indi-
cate that the quantities of these tissue components in the 
breast are determined largely by heritable factors. 
Further  more, each component has properties that may 
inﬂ  uence the risk and progression of breast cancer.
Breast cancer arises from epithelial cells and the 
number and proliferative state of these cells may inﬂ  u-
ence both the radiological density of the breast and the 
probability of genetic damage that can give rise to cancer. 
In addition, collagen and the stromal matrix are products 
of stromal cells, which may, through mechanical and 
other properties, facilitate tumor invasion. Interactions 
between stroma and epithelium are known to inﬂ  uence 
breast development and the changes in breast structure 
that take place during pregnancy, lactation, and 
involution and during tumorigenesis. Th  e extracellular 
matrix, which comprises collagens, ﬁ  bronectin, laminins, 
polysaccharides, and proteoglycans, plays a key role in 
these processes, and there is a large and rapidly growing 
body of literature on the molecules that mediate how the 
extracellular matrix inﬂ  uences the epithelium (see [52-55] 
for reviews). Proteoglycans (see ‘Biological plausi  bility of 
the association of mammographic density and breast 
cancer risk’ section above) bind growth factors, contri-
bute to the mechanical integrity of tissues, may reﬂ  ect 
the stiﬀ   ness of breast tissue, and can modify tissue 
behavior [55]. To date, there has been limited application 
of these basic science ﬁ   ndings to understanding the 
association between PMD and risk of breast cancer. 
Animal models now being developed may clarify the 
biological mechanisms that underlie the association of 
PMD with breast cancer risk.
Potential clinical applications of mammographic density
Mammographic screening
Th   e evidence given above shows that women undergoing 
screening for breast cancer with mammography are 
heterogeneous with respect to cancer risk and the ease 
with which breast cancer can be detected by mammo-
graphy. Women with extensive PMD are doubly dis-
advan  taged as they are both at higher risk of developing 
breast cancer and at greater risk that cancer will not be 
detected by mammography, because of ‘masking’ by 
density of the radiological signs of cancer. In the presence 
of this underlying heterogeneity in the population under-
going screening, it does not seem likely that screening 
with a single modality and a single screening frequency 
will be optimal. It seems possible that, for women with 
extensive PMD, screening more often than once every 2 
to 3 years and with modalities such as MR or UST in 
addition to mammography would improve cancer 
detection rates at screening and reduce the frequency of 
interval cancers. For women with radio-lucent breast 
tissue and a negative screening mammogram, in whom 
risk is lower and detection easier, re-screening less 
frequently than every 2 to 3 years might be safe. Research 
is required into opti  miz  ing screening frequency and 
modality according to the breast tissue characteristics of 
women. An approach to mammographic screening that 
starts at age 40 and that bases the frequency of screening 
on a women’s age, breast density (by BI-RADS score), and 
other risk factors was recently advocated and shown to 
be cost-eﬀ   ective [56]. However, in an editorial 
accompanying that paper, a number of potential 
limitations of this approach were raised [57]. Th  ese 
limitations include lack of knowledge of the biological 
basis of the risk associated with mammo  graphic density 
and of the eﬀ  ects of density on the risk and detection of 
breast cancer subtypes (see ‘Breast cancer characteristics 
and clinical outcomes’ section below).
Individual risk prediction
Currently, the most widely used method of predicting 
risk of breast cancer in individuals is the Gail model [58], 
which takes into account a woman’s age, age at menarche, 
age at ﬁ  rst live birth, number of previous benign breast 
biopsies, and number of ﬁ  rst-degree relatives with breast 
cancer. Breast density is more strongly associated with 
breast cancer risk than the other variables included in the 
Gail model, and the addition of breast density, measured 
by a manual method tracing, to the Gail model increased 
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statistic, from 0.607 to 0.642 [59]. Tice and colleagues 
[60] developed a predictive model for breast cancer by 
using the BI-RADS classiﬁ   cation; the model had a 
concordance statistic of 0.66. Th  e Gail and Tice models 
have only moderate levels of risk prediction that might be 
improved by the improvements in measuring breast 
density described above.
Breast cancer prevention trials
In contrast to most other risk factors for breast cancer, 
mammographic density can be changed (as described 
below), suggesting that MD might be used as a surrogate 
marker in clinical trials of potential approaches to breast 
cancer prevention. Clinical trials of breast cancer 
prevention require large numbers of subjects and long 
periods of observation and thus are expensive. Th  e 
number of subjects required in a breast cancer prevention 
trial can, however, be reduced by the selection of subjects 
at increased risk of breast cancer. We have carried out a 
long-term dietary intervention study in 4,690 women 
selected because they had mammo  graphic density in 50% 
or more of the breast. During an average follow-up of 
10 years (range of 7 to 17 years), invasive breast cancer was 
detected in 220 women, an observed age-speciﬁ  c incidence 
twice that of women of the same age in the Canadian 
population followed for the same length of time. However, 
a potential limitation of the selection of a high-risk group 
is that the results of such a trial may not be applicable to 
women who are not at increased risk [61].
It would make possible smaller, shorter, and less 
expensive trials of breast cancer prevention strategies if 
there were a breast cancer surrogate that after a short 
period of observation would allow the identiﬁ  cation of 
interventions that would reduce breast cancer incidence. 
To be used as a surrogate for breast cancer, a biomarker 
such as PMD should meet the criteria proposed by 
Prentice [62] and further by Schatzkin and Gail [63]. 
Th   ese are that (a) the marker should be associated with 
risk of breast cancer, (b) the marker should be changed 
by the intervention, and (c) the change in the marker 
should mediate the eﬀ  ect of the intervention on breast 
cancer risk.
In a case control study nested within the ﬁ  rst Inter-
national Breast Cancer Intervention Study (IBIS), a 
random  ized prevention trial of tamoxifen versus placebo, 
Cuzick and colleagues [64] showed that, compared with 
all women in the placebo group, those in the tamoxifen 
group who experienced a 10% or greater reduction in 
breast density had a 63% reduction in breast cancer risk, 
whereas those who took tamoxifen but experienced a 
reduction in PMD of less than 10% had no risk reduction. 
In the placebo arm, breast cancer risk was similar in 
subjects who experienced less than a 10% reduction in 
PMD and those who experienced a greater reduction. 
Th   e authors conclude that the change in PMD 12 to 18 
months after starting treatment is an excellent predictor 
of response to tamoxifen in the preventive setting [64].
Th   ese results (and others) show that PMD is associated 
with risk of breast cancer and is changed by intervention 
with tamoxifen. However, although the change in PMD 
was associated with the eﬀ  ect of tamoxifen on breast 
cancer risk, no evidence is given that the change in PMD 
mediated the eﬀ  ect of tamoxifen on breast cancer risk.
Even if it were convincingly shown that change in PMD 
did mediate the eﬀ  ects of tamoxifen on breast cancer 
risk, it should not be concluded that all other causes of a 
reduction in PMD will reduce risk of breast cancer. For 
example, as discussed above, average PMD decreases 
with increasing age whereas breast cancer incidence 
increases with age. A randomized controlled trial of 
physical activity for 1 year in postmenopausal women, 
which may reduce breast cancer risk, showed that PMD 
was increased as a result of the weight loss associated 
with the intervention [65].
Other interventions that are known to inﬂ  uence PMD 
and breast cancer risk include combined hormone 
therapy (but not estrogen alone), which increases PMD 
and risk of breast cancer [66-68], and a gonadotrophin-
releasing hormone agonist reduces PMD in premeno-
pausal women [69]. It is not yet known whether PMD can 
be used as a surrogate for breast cancer in any of these 
settings. In the IBIS trial, the association observed 
between change in PMD and reduc  tion in breast cancer 
incidence with tamoxifen suggests that change in PMD 
after the initiation of hormone therapy might be useful in 
the prediction of eﬀ  ect in therapeutic settings.
Breast cancer characteristics and clinical outcomes
Tables 3 and 4 show, respectively, summaries of published 
studies that have examined the associations of breast 
density with tumor characteristics and the clinical course 
of breast cancer. To date, most studies examining the 
association of breast density with tumor characteristics 
have used a qualitative measure of density (for example, 
BI-RADS), lacked information on covariates, and diﬀ  ered 
in whether and how the cancer was detected (by screen-
ing or other means).
Tumor characteristics
Studies that have examined the association of breast 
density with tumor characteristics of estrogen receptor 
status, tumor size, and nodal status are summarized in 
Table 3. Th   ese studies vary in size, design, methods used 
to classify mammographic density, and factors adjusted 
for in analysis. Diﬀ  erences in these factors may contribute 
to the inconsistency of the results of the association of 
breast density with tumor characteristics.
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Page 7 of 12Table 3. Summary of studies of the association of mammographic density and tumor characteristics
  Association with
Authors, region      Measurement      Nodal 
(year)  Design  Sample size  of MD  ER status/phenotypea Sizea,b statusa,b Adjustmentsc
Yaghjyan et al. 
[70], USA (2011)
Nested case 
control
1,042 cases 
1,794 controls
Computer-
assisted
Case control:
Increased risk of ER+ and 
ER− tumors (greater for 
ER−)
Increased risk of PR+ and 
PR− and HER2− and HER2+ 
tumors
Increased risk 
for tumors 
>2 cm but 
not for tumors 
<2 cm
Increased 
risk with 
node+ and 
node− 
disease
Age, BMI, age at menarche, 
age at fi  rst birth, parity, age at 
menopause, HRT use, family 
history, history of benign 
breast disease, alcohol intake, 
and smoking
Conroy et al. 
[71], USA (2011)
Nested case 
control
607 cases 
667 controls
Computer-
assisted
Case control:
Increased risk of ER+ 
tumors only
Case only:
ER+ > PMD than ER− cases
n/a n/a Age, ethnicity, BMI, parity, age 
at fi  rst birth, age at menarche, 
menopausal status, HRT use, 
and family history
Ding et al. [72], 
Europe (2010)
Nested case 
control 
370 cases 
1,904 controls
Computer-
assisted
Case control:
Increased risk of ER+ 
tumors only
Increased risk 
for tumors of all 
sizes
Increased 
risk with 
node+ and 
node− 
disease 
Age
Case only:
ER+ > PMD than ER− cases
No 
association
No 
association
Olsen et al. [73], 
Europe (2009)
Cohort 694 cases 
48,052 total
Mixed/dense 
versus fatty
Increased risk of ER+ and 
ER− tumors (greater for 
ER+)
n/a n/a Age
Ziv et al. [74], 
USA (2004)
Cohort 701 cases 
44,811 total
BI-RADS Increased risk of ER+ and 
ER− tumors
n/a n/a  Age, HRT use, BMI, parity, family 
history, menopause, and race
Ma et al. [75], 
USA (2009)
Case control 479 cases 
376 controls
Computer-
assisted
Case control:
Increased risk of ER+/PR+, 
ER−/PR−, HER2−, luminal 
A, and triple-negative 
tumorsd
Case analysis:
Molecular subtyped: 
no association 
n/a n/a Age, family history, BMI, age at 
menarche, parity, age at fi  rst 
birth, menopause, and HRT use
Gierach et al. 
[76], Europe 
(2010 abstract)
Case only 227 cases Computer-
assisted
No signifi  cant diff  erence 
in PMD between luminal 
A, luminal B, HER2+, 
basal-like, or unclassifi  ed 
tumorsd
n/a n/a Not available (abstract only)
Arora et al. [77], 
USA (2010)
Case only 1,323 cases BI-RADS Molecular subtype: 
no association 
No 
association
No 
association
Age
Yang et al. [78], 
USA (2008)
Case only 198 cases BI-RADS Molecular subtyped: 
no association 
n/a n/a None
Cil et al. [79], 
Canada (2009)
Case only 335 cases Wolfe score No association No 
association
No 
association
None
Nickson and 
Kavanagh [86], 
Australia (2009)
Case only  1,348 cases Semi-
automated
n/a No 
association
n/a Age, HRT use, and family 
history
Ghosh et al. [80], 
USA (2008)
Case only 286 cases Computer-
assisted
No association No 
association
n/a Age, parity, BMI, family history, 
and HRT use
Porter et al. [87], 
Europe (2007)
Case only 759 cases BI-RADS n/a Positive (screen-
detected)
No 
association
None
Fasching et al. 
[81], Europe 
(2006)
Case only 434 cases BI-RADS No association Negative No 
association
None
Continued overleaf
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  Association with
Authors, region      Measurement      Nodal 
(year)  Design  Sample size  of MD  ER status/phenotypea Sizea,b statusa,b Adjustmentsc
Aiello et al. [82], 
USA (2005)
Case only 546 cases BI-RADS No association Positive  Positive Age, BMI, menopause, and age 
at fi  rst birth
Morishita et 
al. [83], Japan 
(2005)
Case only 163 cases BI-RADS No association  No 
association
n/a None
Roubidoux et al. 
[84], USA (2004)
Case only 121 cases BI-RADS No association Positive No 
association
Age
Sala et al. [88], 
Europe (2000)
Nested case 
control
875 cases Wolfe n/a Positive  Positive None
Hinton et al. 
[85], Europe 
(1985)
Case only 337 cases Wolfe DY pattern associated 
with greater frequency of 
ER+ versus ER− tumors
n/a n/a None
Boyd et al. [89], 
Canada (1982)
Case only 183 cases Wolfe n/a No 
association
No 
association
None
aNo association: association is not statistically signifi  cant. bPositive: higher percent mammographic density (PMD) associated with higher tumor size or higher 
frequency of positive nodal status (node+); negative (inverse) association: higher PMD associated with smaller tumor size or lower frequency of positive nodal status 
(node+). cFactors included in the analysis of risk associated with mammographic density or of the association of mammographic density with tumor characteristics. 
dMolecular subtypes determined by immunohistochemistry. BI-RADS, Breast Imaging-Reporting and Data System; BMI, body mass index; DY, dysplastic; ER, estrogen 
receptor; HRT, hormone replacement therapy; MD, mammographic density; n/a: not assessed; PR, progesterone receptor.
Table 4. Summary of studies of mammographic density and risk of second breast cancers
  Results
Authors,   Study  Median  Measurement      HR 
region (year)  population  follow-up  of MD  Eventsb Number  (95%  CI)  Adjustmentsa Comments
Habel et al. [91], 
USA (2010)
935 patients 
with DCIS
8 years Planimeter
Highest versus 
lowest quintile of 
dense area
All 228 1.8 
(1.2 to 2.9)
Age, BMI, 
treatment, 
and diagnosis 
year
Similar HR in 
subgroups 
of age, BMI, 
treatment, and 
menopausal 
status
Ips. 164 1.7 
(1.0 to 2.9)
Cont. 59 3.0 
(1.3 to 6.9)
Hwang et al. 
[93], USA (2007)
3,274 patients 
with DCIS
39 months BI-RADS
High (3 or 4) versus 
low (1 or 2)
All inv. 133 1.4 
(0.9 to 2.1)
Age and 
radiation 
treatment
No interaction 
of density 
with radiation 
treatment
Ips. inv. 83 1.0 
(0.6 to 1.6)
Cont. inv. 52 3.1 
(1.6 to 6.1)
Habel et al. [90], 
USA (2004)
334 patients 
with DCIS
11 years Planimetry
>75% versus <25% 
PMD
All 112 2.8 
(1.3 to 6.1)
Age, BMI, 
and radiation 
treatment
No interaction 
with radiation 
treatment or 
menopausal 
status
Ips. 80 3.0 
(1.2 to 7.5)
Cont. 28 3.4 
(0.7 to 16.2)
Cil et al. [79], 
Canada (2009)
335 patients 
with invasive 
breast cancer
8 years Wolfe score
High versus low 
Wolfe score
Ips. inv. 34 5.7 
(1.6 to 20.0)
Age, 
menopause, 
and radiation 
treatment
Association 
stronger in those 
who did not 
receive radiation 
treatment
Dist. inv. 31 No association 
(HR not given)
Park et al. [92], 
USA (2008)
136 patients 
with invasive 
breast cancer
7.7 years Computer- assisted
>75% versus <25% 
PMD
Ips. inv. 19 3.4 
(1.6 to 7.5)
BMI
Cont./
Dist. inv.
25 No association 
(HR not given)
aFactors included in the analysis of mammographic density and risk of second breast cancer. bEvents include in situ and invasive cancer unless specifi  ed as invasive 
(inv.). All, all second breast cancers; BI-RADS, Breast Imaging-Reporting and Data System; BMI, body mass index; CI, confi  dence interval; Cont., second cancer in 
contralateral breast; DCIS, ductal carcinoma in situ; Dist, distant metastasis; HR, hazard ratio; Ips, second cancer in ipsilateral breast; MD, mammographic density; PMD, 
percent mammographic density.
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density with hormone receptor status or molecular 
pheno  type [70-85], most found no associations. More 
extensive density was found to be associated with risk of 
ER+ tumors in 6 studies [70-75] and of ER− tumors in 4 
studies [70,73-75]. Of 12 studies that examined tumor 
size in relation to breast density [70,72,77,79-84,86-89], 4 
found larger tumors [82,84,87,88] and 1 found smaller 
tumors [81] associated with more extensive density. Th  e 
remainder found no association. Ten studies examined 
nodal  status  [70, 72, 77, 79, 81, 82, 84, 87-89],  and  2  found 
nodal involvement to be more frequent in those with 
extensive density [82,88] and the remainder found no 
association. In addition, Yaghjyan and colleagues [70] 
found that the associations between breast density and 
breast cancer were stronger for in situ than for invasive 
tumors and for high-grade than for low-grade tumors.
Risk of second breast cancer
Studies that have examined risk of a second invasive or in 
situ breast cancer are summarized in Table 4. Four [79, 
90-92] of the ﬁ  ve [79,90-93] studies show an increased 
risk of a second cancer in the ipsilateral breast, and three 
[90,91,93] of the ﬁ   ve show an increased risk in the 
contralateral breast. Only one [79] of the three [79,91,93] 
studies to examine the potential modifying role of radia-
tion therapy found evidence that risk of a second breast 
cancer was higher in those who did not receive radiation.
Women with higher density have been shown to have a 
higher risk of dying from breast cancer compared with 
those with lower density, but this is due largely to the 
increased breast cancer incidence associated with density 
[73,94]. In terms of survival after a breast cancer diagnosis, 
one study reported a non-signiﬁ  cant trend to better survival 
in women with dense breasts [68], and another reported 
that women with mixed/dense breasts had a signiﬁ  cantly 
lower risk of death from any cause or from breast cancer 
speciﬁ  cally (case fatality rates of 60% and 53%, respectively) 
compared with women with fatty breasts [73].
Summary
Th   ere is now extensive evidence that extensive PMD is a 
strong risk factor for breast cancer and is associated with 
large relative and attributable risks for the disease. As 
discussed above (in the ‘Breast cancer prevention trials’ 
section), unlike most breast cancer risk factors, PMD can 
be changed. Work now in progress is likely to improve 
measurement of PMD, understanding of the genetics and 
biological basis of the association of PMD with breast 
cancer risk, and the clinical signiﬁ   cance of change in 
PMD. Future prospects for the application of PMD 
include improvements in mammographic screening, risk 
prediction in individuals, breast cancer prevention 
research, and clinical decision making.
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